MAP2K7 and neoplasm: Numerous studies showed a TPL2-driven MEK/ERK1/2 activation pathway relevant in a number of cancers although the tumor-promoting or anti-tumor effect of TPL2 involvement is varying from one to another (Lee et al., 2015[30]).